Hereditary peripheral neuropathy
MONDO:0020127An instance of peripheral neuropathy that is caused by an inherited genomic modification in an individual.
Also known as: genetic peripheral neuropathy
415 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental cancer drug study halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control TerminatedThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control TerminatedThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase: PHASE2, PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control TerminatedThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control TerminatedThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control TerminatedThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control TerminatedThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase: PHASE3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control TerminatedThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase: PHASE1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
Tiny incision, big relief? ultrasound procedure challenges carpal tunnel surgery
Symptom relief TerminatedThis study compared a new, minimally invasive ultrasound-guided procedure to standard surgery for carpal tunnel syndrome. The goal was to see if the new technique could provide similar relief with a smaller incision and faster recovery. Only 7 people were enrolled before the stud…
Phase: NA • Sponsor: Ramsay Générale de Santé • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Can a blood injection boost carpal tunnel surgery results?
Symptom relief TerminatedThis study looked at whether adding platelet-rich plasma (PRP) to standard carpal tunnel release surgery helps people with severe carpal tunnel syndrome. The trial planned to enroll 15 adults with severe nerve damage. It compared surgery with PRP to surgery alone. The study was t…
Phase: NA • Sponsor: Michael Fredericson, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Tafamidis tablet vs capsule: which works better?
Knowledge-focused TerminatedThis early-stage study aimed to compare how a tablet form of tafamidis is absorbed in the body compared to the existing capsule form. It involved 24 healthy adults who took a single dose of each form under fed conditions. The study was terminated early, so results may be limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused TerminatedThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Hidden heart condition: study seeks to uncover missed diagnosis in heart failure patients
Knowledge-focused TerminatedThis study aims to find out how common transthyretin amyloidosis cardiomyopathy (ATTR-CM) is in Russian patients with a certain type of heart failure. Researchers will review medical records and then invite some patients for extra heart tests to confirm or rule out ATTR-CM. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused TerminatedThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC